StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio gross margin

Gross margin is gross profit as a percentage of revenue.

Regenxbio's gross margin for the twelve months ending Dec 31, 2024 was 59.7%. For fiscal 2024 it was 59.7%, against 58.8% the year before. The highest annual figure on record is 98.7% in fiscal 2015.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 202459.7%+1.0
FY2023Dec 31, 202358.8%+7.2
FY2022Dec 31, 202251.6%−37.4
FY2021Dec 31, 202189.0%+12.1
FY2020Dec 31, 202076.9%+0.3
FY2019Dec 31, 201976.6%−19.0
FY2018Dec 31, 201895.6%+12.0
FY2017Dec 31, 201783.6%−14.3
FY2016Dec 31, 201697.9%−0.8
FY2015Dec 31, 201598.7%+0.7
FY2014Dec 31, 201498.0%+0.8
FY2013Dec 31, 201397.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2024Dec 31, 202470.2%+20.8
Q3 FY2024Sep 30, 202448.8%−8.3
Q2 FY2024Jun 30, 202452.5%−0.0
Q1 FY2024Mar 31, 202472.6%−5.9
Q4 FY2023Dec 31, 202349.4%−9.8
Q3 FY2023Sep 30, 202357.2%+6.5
Q2 FY2023Jun 30, 202352.6%−7.8
Q1 FY2023Mar 31, 202378.5%+49.3
Q4 FY2022Dec 31, 202259.2%−35.0
Q3 FY2022Sep 30, 202250.6%−3.6
Q2 FY2022Jun 30, 202260.3%+4.9
Q1 FY2022Mar 31, 202229.3%−45.1
Q4 FY2021Dec 31, 202194.2%+42.0
Q3 FY2021Sep 30, 202154.2%−28.3
Q2 FY2021Jun 30, 202155.4%−16.3
Q1 FY2021Mar 31, 202174.3%−6.4
Q4 FY2020Dec 31, 202052.2%−15.6
Q3 FY2020Sep 30, 202082.4%−0.6
Q2 FY2020Jun 30, 202071.7%−3.8
Q1 FY2020Mar 31, 202080.7%−16.0
Q4 FY2019Dec 31, 201967.8%−25.2
Q3 FY2019Sep 30, 201983.0%−7.2
Q2 FY2019Jun 30, 201975.5%−14.8
Q1 FY2019Mar 31, 201996.7%−1.5
Q4 FY2018Dec 31, 201893.0%+76.5
Q3 FY2018Sep 30, 201890.3%−9.7
Q2 FY2018Jun 30, 201890.3%−9.6
Q1 FY2018Mar 31, 201898.2%+15.8
Q4 FY2017Dec 31, 201716.5%–
Q3 FY2017Sep 30, 2017100.0%–
Q2 FY2017Jun 30, 201799.9%–
Q3 FY2016Sep 30, 201682.4%–

More Regenxbio figures

See a number that looks wrong?